Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc. is a biopharmaceutical company dedicated to developing precision genetic medicine for the treatment of rare neuromuscular diseases. With an emphasis on RNA-targeted therapeutics, Sarepta's primary focus is on Duchenne muscular dystrophy (DMD), a severe and progressive muscle degeneration disorder. The company's pipeline features innovative gene therapy and RNA-based technologies designed to address the underlying genetic cause of DMD, offering potential to alter the disease trajectory. Sarepta Therapeutics engages primarily with the healthcare and life sciences industries, collaborating with academic institutions and leveraging advanced bioinformatics tools for drug discovery and development. Situated at the forefront of genetic medicine, Sarepta plays a significant role in pioneering treatments that could revolutionize care for rare diseases, making substantial impacts on both patients' lives and the broader biopharmaceutical landscape.